Noteworthy is the presence of a nitrocatechol moiety in two catechol O-methyltransferase (COMT) inhibitors such as tolcapone and entacapone, included in the clinical treatment of PD (Li et al., 2017; Artusi et al., 2021). The gene discussed is COMT; the disease is Parkinson disease.